PHD Biosciences
Private Company
Total funding raised: $1.8M
Overview
Founded in 2011, PHD Biosciences is a private, commercial-stage biotech developing prescription and non-prescription products in oncology and immunology. The company boasts a seasoned leadership team with proven track records in drug development and commercialization, and has secured significant non-dilutive funding to advance its programs. PHD operates with a lean, project-focused model, aiming to translate its scientific innovations into marketed products through strategic development and partnerships.
Technology Platform
Expertise in advanced chemistry and polymer-based drug delivery systems, particularly for topical and systemic applications, including novel methodologies for designing moieties and nanoparticle self-assembly.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
PHD operates in the highly competitive oncology and immunology sectors, competing against large pharmaceutical companies and well-funded biotechs. Its differentiation likely hinges on its specific drug delivery technology and the development efficiency afforded by its experienced, lean team.